Skip to main content

Further pharma investment at Lonza

14th December 2020

Submitted by:

Andrew Warmington

Lonza has recently announced three specific investments in the pharma sector in recent weeks. It will build two new customer-dedicated conjugation suites for antibody-drug conjugates (ADCs) at Visp, Switzerland, while adding particle engineering and drug product development at two sites in the US.

The ADCs investment is part of strategic collaboration for bioconjugation with an unnamed global biopharma company. The high throughput bioconjugation suites will be built out within a pre-existing shell, covering 1500 m2 of active manufacturing space and linked to established QC labs, logistics and other central services.

The suites will be able to handle highly potent materials for cancer therapies and will initially manufacture two therapies. Operations are expected to start from the end of 2022, with around 20 staff working there.

This follows the recent opening first of two manufacturing suites at Visp for the manufacture of ADC linkers or payloads. The facility is already manufacturing at commercial scale for a biopharmaceutical customer, following successful validation. It can handle compounds with OELs down to 1 ng/m3.

The company said at the time that the new suites will boost its capabilities “to provide fully scalable HPAPI and ADC solutions from lab to commercialisation, supporting the accelerated timelines that many drug programmes in this category require”. The second suite will become available in early 2021.

Lonza has also announced a “significant investment” to expand its particle engineering and drug product capabilities at Bend, Oregon, in response to growing general demand. The first suite of 11 is due online this month, adding to early-phase spray-drying, tabletting and encapsulation capabilities.

The whole facility will be completed in May 2022 and will also feature site spray-drying, hot melt extrusion and melt-spray-congeal processing. Non-cGMP capability for formulation and process development will also be expanded with one new suite.

Finally, Lonza will make announced additional investments in its oral drug product development and manufacturing capabilities at Tampa, Florida, where it has already spent $15 million to expand and upgrade it over the past two years.

This includes upgrading the laboratories to handle highly potent material handling, new Gerteis roller compaction equipment incorporating high containment, for dry granulation processing. The latter, Lonza said, complements its HPAPI processing capabilities at Visp, which has one of the world’s largest capacities for HPAPI development and manufacturing.

UPL to split out specialities

Indian agrochemicals giant UPL has announced plans to transfer its speciality chemicals business, including agrochemical

Submitted by:

Andrew Warmington

AI for SAPs

Together with Algo Artis, Japan’s Nippon Shokubai has developed an algorithm-based means for the production

Submitted by:

Andrew Warmington

Nippon Shokubai's API Facility in Japan

Nucleic acid API boost

Nippon Shokubai is to expand its GMP capacity for nucleic APIs tenfold It will install

Submitted by:

Andrew Warmington

Flamma's facility in Dalian

Flamma opens in China

Italian CDMO Flamma Group has officially opened its new cGMP plant at Dalian, China, where

Submitted by:

Andrew Warmington

GL Chemtec has opened a new kilo lab

GL Chemtec completes kilo lab

CDMO GL Chemtec has announced the completion of a cGMP kilo lab at Oakville, Ontario

Submitted by:

Andrew Warmington

Sterling's facility at Deeside, UK

CDMOs in ADC investments

Five CDMOs across the world have separately announced investments in antibody-drug conjugates (ADCs). Piramal Pharma is

Submitted by:

Andrew Warmington

Halozyme has dropped its approach to buy Evotec

Halozyme abandons Evotec bid

San Diego-based biopharmaceutical company Halozyme Therapeutics has withdrawn the offer it made for Evotec after

Submitted by:

Andrew Warmington

Afyren Neoxy plant

Milestones for two greentech firms

Afyren has achieved continuous production at its Afyren Neoxy plant at Clermont-Ferrand (pictured)

Submitted by:

Andrew Warmington

Origin by Ocean derives its materials from sargassum

CABB in algae biorefinery deal

CABB has agreed a strategic partnership to establish a first-in-kind algae biorefinery at its site at Kokkola

Submitted by:

Andrew Warmington

First waste-based biosurfactants

Belgian start-up AmphiStar has launched what it claims are the first fully upcycled biobased surfactants

Submitted by:

Andrew Warmington

Aether to supply Seqens

Indian firm Aether Industries has entered into a manufacturing agreement with Chemoxy International, a UK-based

Submitted by:

Andrew Warmington

New model for biocatalysts

BASF, the Austrian Research Centre of Industrial Biotechnology (ACIB) and the University of Graz in

Submitted by:

Andrew Warmington

CBE JU funds 31 more projects

The Circular Bio-based Europe Joint Undertaking (CBE JU), a €2 billion partnership between the EU

Submitted by:

Andrew Warmington

Ribbon cutting ceremony at Lubrizol's new office

Lubrizol opens London office

Lubrizol has opened a new office in Hammersmith, London. This will be home to a

Submitted by:

Andrew Warmington

Sudarshan to buy Heubach

India’s Sudarshan Chemical Industries (SCIL) has entered into a definitive agreement to acquire the Heubach

Submitted by:

Andrew Warmington

Alliance in natural fragrances

Sensegen, a US-based specialist in biotech-enabled fragrances, notably a new class of natural musk raw

Submitted by:

Andrew Warmington

Croda breaks ground in China

Croda International has broken ground for a low-carbon, multi-purpose production facility on a greenfield site

Submitted by:

Andrew Warmington

CCT collaboration for Givaudan

Flavours and fragrances giant Givaudan has agreed a research collaboration for the development of sustainable

Submitted by:

Andrew Warmington

REACH Authorisation

Candidate List ‘reaches’ 250

The European Chemicals Agency (ECHA) has added three more substances to the Candidate List of

Submitted by:

Andrew Warmington

Staff at Brenntag's newly acquired Czech site

CO2-free distribution site first

Brenntag has officially inaugurated what it claims to be the first CO2-emission-free chemical distribution site

Submitted by:

Andrew Warmington